Loading…
Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway
Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysacc...
Saved in:
Published in: | Fundamental & clinical pharmacology 2015-10, Vol.29 (5), p.462-471 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183 |
---|---|
cites | cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183 |
container_end_page | 471 |
container_issue | 5 |
container_start_page | 462 |
container_title | Fundamental & clinical pharmacology |
container_volume | 29 |
creator | Xu, Yingzhen Zhang, Ruyi Li, Chunli Yin, Xue Lv, Changjun Wang, Yaoqi Zhao, Wenxiang Zhang, Xiuli |
description | Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway. |
doi_str_mv | 10.1111/fcp.12138 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1713527838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1713527838</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</originalsourceid><addsrcrecordid>eNp1kEtv1TAQRi0EopfCgj-AvIRFWj8SP5bVvfShFugCytJynLmNSxKnsUObf1-X23bHbEaaOfNpdBD6SMkBzXW4deMBZZSrV2hFS8kKxYh4jVZECllwregeehfjDSFUEireoj0mGKWlrlbo7wbue2gghd43fgBsU4Jhtgkitm5OgLt5uMZ-uJmnJbdmdtDgesGdH8MYuiVa51o7-QbyFvdhjoBTO4X5us2D1tc--TDgsMXfji7P8WhTe2eX9-jN1nYRPjz1ffTr-OvP9Wlx8ePkbH10UbiSaVVoy4XTTtYlJVKDVFYqXZcVKaFxdeWIcLV1gsk80IzVTVXVggC3SmtOqeL76PMud5zC7Qwxmd5HB11nB8ivGiopr5hU_BH9skPdFGKcYGvGyfd2Wgwl5lGzyZrNP82Z_fQUO9fZ3gv57DUDhzvgznew_D_JHK8vnyOL3YWPCe5fLuz0xwjJZWV-fz8xV5vNFT09F0bxB_VNl3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1713527838</pqid></control><display><type>article</type><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</creator><creatorcontrib>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</creatorcontrib><description>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</description><identifier>ISSN: 0767-3981</identifier><identifier>EISSN: 1472-8206</identifier><identifier>DOI: 10.1111/fcp.12138</identifier><identifier>PMID: 26211495</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>acute lung injury ; Acute Lung Injury - chemically induced ; Acute Lung Injury - enzymology ; Acute Lung Injury - genetics ; Acute Lung Injury - pathology ; Acute Lung Injury - prevention & control ; Animals ; Anti-Inflammatory Agents - pharmacology ; Bronchoalveolar Lavage Fluid - chemistry ; Cytokines - metabolism ; Cytoprotection ; dexmedetomidine ; Dexmedetomidine - pharmacology ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Enzyme Activation ; inflammation ; Inflammation Mediators - metabolism ; lipopolysaccharide ; Lipopolysaccharides ; Lung - drug effects ; Lung - enzymology ; Lung - pathology ; Male ; MAP Kinase Signaling System - drug effects ; Mice ; mitogen-activated protein kinase ; Mitogen-Activated Protein Kinases - metabolism ; Neutrophil Infiltration - drug effects ; Phosphorylation ; Pulmonary Edema - chemically induced ; Pulmonary Edema - enzymology ; Pulmonary Edema - prevention & control ; Time Factors ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Transcription, Genetic - drug effects</subject><ispartof>Fundamental & clinical pharmacology, 2015-10, Vol.29 (5), p.462-471</ispartof><rights>2015 Société Française de Pharmacologie et de Thérapeutique</rights><rights>2015 Société Française de Pharmacologie et de Thérapeutique.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</citedby><cites>FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26211495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yingzhen</creatorcontrib><creatorcontrib>Zhang, Ruyi</creatorcontrib><creatorcontrib>Li, Chunli</creatorcontrib><creatorcontrib>Yin, Xue</creatorcontrib><creatorcontrib>Lv, Changjun</creatorcontrib><creatorcontrib>Wang, Yaoqi</creatorcontrib><creatorcontrib>Zhao, Wenxiang</creatorcontrib><creatorcontrib>Zhang, Xiuli</creatorcontrib><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><title>Fundamental & clinical pharmacology</title><addtitle>Fundam Clin Pharmacol</addtitle><description>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</description><subject>acute lung injury</subject><subject>Acute Lung Injury - chemically induced</subject><subject>Acute Lung Injury - enzymology</subject><subject>Acute Lung Injury - genetics</subject><subject>Acute Lung Injury - pathology</subject><subject>Acute Lung Injury - prevention & control</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Bronchoalveolar Lavage Fluid - chemistry</subject><subject>Cytokines - metabolism</subject><subject>Cytoprotection</subject><subject>dexmedetomidine</subject><subject>Dexmedetomidine - pharmacology</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Enzyme Activation</subject><subject>inflammation</subject><subject>Inflammation Mediators - metabolism</subject><subject>lipopolysaccharide</subject><subject>Lipopolysaccharides</subject><subject>Lung - drug effects</subject><subject>Lung - enzymology</subject><subject>Lung - pathology</subject><subject>Male</subject><subject>MAP Kinase Signaling System - drug effects</subject><subject>Mice</subject><subject>mitogen-activated protein kinase</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Neutrophil Infiltration - drug effects</subject><subject>Phosphorylation</subject><subject>Pulmonary Edema - chemically induced</subject><subject>Pulmonary Edema - enzymology</subject><subject>Pulmonary Edema - prevention & control</subject><subject>Time Factors</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Transcription, Genetic - drug effects</subject><issn>0767-3981</issn><issn>1472-8206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kEtv1TAQRi0EopfCgj-AvIRFWj8SP5bVvfShFugCytJynLmNSxKnsUObf1-X23bHbEaaOfNpdBD6SMkBzXW4deMBZZSrV2hFS8kKxYh4jVZECllwregeehfjDSFUEireoj0mGKWlrlbo7wbue2gghd43fgBsU4Jhtgkitm5OgLt5uMZ-uJmnJbdmdtDgesGdH8MYuiVa51o7-QbyFvdhjoBTO4X5us2D1tc--TDgsMXfji7P8WhTe2eX9-jN1nYRPjz1ffTr-OvP9Wlx8ePkbH10UbiSaVVoy4XTTtYlJVKDVFYqXZcVKaFxdeWIcLV1gsk80IzVTVXVggC3SmtOqeL76PMud5zC7Qwxmd5HB11nB8ivGiopr5hU_BH9skPdFGKcYGvGyfd2Wgwl5lGzyZrNP82Z_fQUO9fZ3gv57DUDhzvgznew_D_JHK8vnyOL3YWPCe5fLuz0xwjJZWV-fz8xV5vNFT09F0bxB_VNl3Y</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Xu, Yingzhen</creator><creator>Zhang, Ruyi</creator><creator>Li, Chunli</creator><creator>Yin, Xue</creator><creator>Lv, Changjun</creator><creator>Wang, Yaoqi</creator><creator>Zhao, Wenxiang</creator><creator>Zhang, Xiuli</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</title><author>Xu, Yingzhen ; Zhang, Ruyi ; Li, Chunli ; Yin, Xue ; Lv, Changjun ; Wang, Yaoqi ; Zhao, Wenxiang ; Zhang, Xiuli</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>acute lung injury</topic><topic>Acute Lung Injury - chemically induced</topic><topic>Acute Lung Injury - enzymology</topic><topic>Acute Lung Injury - genetics</topic><topic>Acute Lung Injury - pathology</topic><topic>Acute Lung Injury - prevention & control</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Bronchoalveolar Lavage Fluid - chemistry</topic><topic>Cytokines - metabolism</topic><topic>Cytoprotection</topic><topic>dexmedetomidine</topic><topic>Dexmedetomidine - pharmacology</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Enzyme Activation</topic><topic>inflammation</topic><topic>Inflammation Mediators - metabolism</topic><topic>lipopolysaccharide</topic><topic>Lipopolysaccharides</topic><topic>Lung - drug effects</topic><topic>Lung - enzymology</topic><topic>Lung - pathology</topic><topic>Male</topic><topic>MAP Kinase Signaling System - drug effects</topic><topic>Mice</topic><topic>mitogen-activated protein kinase</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Neutrophil Infiltration - drug effects</topic><topic>Phosphorylation</topic><topic>Pulmonary Edema - chemically induced</topic><topic>Pulmonary Edema - enzymology</topic><topic>Pulmonary Edema - prevention & control</topic><topic>Time Factors</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Transcription, Genetic - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yingzhen</creatorcontrib><creatorcontrib>Zhang, Ruyi</creatorcontrib><creatorcontrib>Li, Chunli</creatorcontrib><creatorcontrib>Yin, Xue</creatorcontrib><creatorcontrib>Lv, Changjun</creatorcontrib><creatorcontrib>Wang, Yaoqi</creatorcontrib><creatorcontrib>Zhao, Wenxiang</creatorcontrib><creatorcontrib>Zhang, Xiuli</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Fundamental & clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Yingzhen</au><au>Zhang, Ruyi</au><au>Li, Chunli</au><au>Yin, Xue</au><au>Lv, Changjun</au><au>Wang, Yaoqi</au><au>Zhao, Wenxiang</au><au>Zhang, Xiuli</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway</atitle><jtitle>Fundamental & clinical pharmacology</jtitle><addtitle>Fundam Clin Pharmacol</addtitle><date>2015-10</date><risdate>2015</risdate><volume>29</volume><issue>5</issue><spage>462</spage><epage>471</epage><pages>462-471</pages><issn>0767-3981</issn><eissn>1472-8206</eissn><abstract>Dexmedetomidine (Dex) is widely used for sedation in intensive care units and can be used as an adjunct to anesthetics. Previous studies have demonstrated that Dex has anti‐inflammatory property. In this study, we aim to explore the potential therapeutic effects and mechanisms of Dex on lipopolysaccharide (LPS)‐induced acute lung injury (ALI) in mice. To induce ALI, mice were intraperitoneally injected with LPS, while Dex was treated 1 h before LPS injection. The inflammation of lung tissues was evaluated by HE stain, and bronchoalveolar lavage fluid (BALF) was obtained after 6 h to measure protein concentrations. We also used an enzyme‐linked immunosorbent assay to detect the secretion levels of proinflammatory cytokines in the serum. Western blotting method was adopted to observe changes in mitogen‐activated protein kinases and downstream nuclear transcription factors. The results showed that pretreatment with Dex considerably reduced neutrophil infiltration and pulmonary edema, and significantly reduced protein concentrations in the BALF, as well as suppressed LPS‐induced elevation of proinflammatory cytokines (TNF‐α and IL‐1β) in the serum. In addition, we observed that the molecular mechanism of Dex‐mediated anti‐inflammation is associated with decreasing phosphorylation of MKK4, MMK3/6, ERK1/2, p38MAPK, and JNK, and diminishing activation of Elk‐1, c‐Jun, and ATF‐2. Dex could attenuate ALI induced by LPS in mice, and this effect may be mediated through the inhibition of MAPK pathway.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26211495</pmid><doi>10.1111/fcp.12138</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0767-3981 |
ispartof | Fundamental & clinical pharmacology, 2015-10, Vol.29 (5), p.462-471 |
issn | 0767-3981 1472-8206 |
language | eng |
recordid | cdi_proquest_miscellaneous_1713527838 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | acute lung injury Acute Lung Injury - chemically induced Acute Lung Injury - enzymology Acute Lung Injury - genetics Acute Lung Injury - pathology Acute Lung Injury - prevention & control Animals Anti-Inflammatory Agents - pharmacology Bronchoalveolar Lavage Fluid - chemistry Cytokines - metabolism Cytoprotection dexmedetomidine Dexmedetomidine - pharmacology Disease Models, Animal Dose-Response Relationship, Drug Enzyme Activation inflammation Inflammation Mediators - metabolism lipopolysaccharide Lipopolysaccharides Lung - drug effects Lung - enzymology Lung - pathology Male MAP Kinase Signaling System - drug effects Mice mitogen-activated protein kinase Mitogen-Activated Protein Kinases - metabolism Neutrophil Infiltration - drug effects Phosphorylation Pulmonary Edema - chemically induced Pulmonary Edema - enzymology Pulmonary Edema - prevention & control Time Factors Transcription Factors - genetics Transcription Factors - metabolism Transcription, Genetic - drug effects |
title | Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T22%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dexmedetomidine%20attenuates%20acute%20lung%20injury%20induced%20by%20lipopolysaccharide%20in%20mouse%20through%20inhibition%20of%20MAPK%20pathway&rft.jtitle=Fundamental%20&%20clinical%20pharmacology&rft.au=Xu,%20Yingzhen&rft.date=2015-10&rft.volume=29&rft.issue=5&rft.spage=462&rft.epage=471&rft.pages=462-471&rft.issn=0767-3981&rft.eissn=1472-8206&rft_id=info:doi/10.1111/fcp.12138&rft_dat=%3Cproquest_cross%3E1713527838%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4298-9a36c9c7b41079e78a789b4504edcb5c06cbac62704e922bd55b60e3a89931183%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1713527838&rft_id=info:pmid/26211495&rfr_iscdi=true |